We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Selection of Neuroprotective Therapy in Patients with Chronic Cerebral Ischemia Taking Account of the Synergism of Drug Interactions.
- Authors
Gromova, O. A.; Torshin, I. Yu.; Putilina, M. V.; Semenov, V. A.; Rudakov, K. V.
- Abstract
Objective. To optimize selection of neuroprotective treatment protocols in patients with chronic cerebral ischemia taking account of synergism in drug interactions for an individual personalized approach to increase treatment efficacy. Materials and Methods. Differential chemoreactome analysis of synergism between ethylmethylhydroxypyridine succinate (EMHPS) and a number of single-component neuroprotective substances (piracetam, vinpocetine, citicoline, choline alfoscerate); proteome analysis of polypeptide neuroprotectors (Cerebrolysin and others); expert analysis of the composition of a multicomponent neuroprotector (Cytoflavin). Results. Piracetam, citicoline (Neupilept), and choline alfoscerate (Cereton) effectively enhanced the pharmacological properties of EMHPS. Expert assessments of synergism between the properties of EMHPS, polypeptide neuroprotectors (Cerebrolysin), and other multicomponent formulations (Cytoflavin), which are also used in the adjuvant therapy in combination with EMHPS, are presented. Conclusions. In real clinical practice there is particular interest in objective evaluation of combined treatment protocols. EMHPS can provide a favorable background for maximizing treatment efficacy using additional drugs.
- Subjects
DRUG synergism; DRUG interactions; CEREBRAL ischemia; NEUROPROTECTIVE agents; PROTEOMICS
- Publication
Neuroscience & Behavioral Physiology, 2021, Vol 51, Issue 4, p430
- ISSN
0097-0549
- Publication type
Article
- DOI
10.1007/s11055-021-01088-0